-The Times of India CHENNAI: The US Food and Drug Administration (FDA) has rapped pharma giant Hospira for serious lapses in manufacturing of drugs at its Sriperumbudur unit. The US agency has warned the firm that this could result in drugs made at the plant not being allowed entry into the US. Hospira, in a regulatory filing, said it had received a warning letter from the agency . The letter followed an...

-The Telegraph Hyderabad: Thousands of Bastar tribals have fled to neighbouring Andhra Pradesh since Sunday to escape the security forces' combing of areas around the Sukma-Jagdalpur road following Saturday's ambush. Although exact figures are not available yet, Andhra district officials say some 10,000 to 15,000 people - mostly tribals but including some middle-class traders - have entered the Khammam and Warangal districts through Bhadrachalam, Chintoor and Venkatapuram. "This is the worst time for...

-The Business Standard USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly The following two quotes from the United States Food and Drug Administration (FDA) news releases may help put the Ranbaxy controversy in perspective. The first sums up what it is that drives the FDA and the second is typical of the challenge the pharmaceutical industry faces. (1) "The consent...

-The Economic Times DANTEWADA: With both the Congress and BJP advocating an intensification of the military campaign against the Naxals, and the UPA government at the Centre even committing more troops to Chhattisgarh, local development in the state could become a casualty in the crossfire. "An outside force is less capable of discriminating between Naxals and villagers," says Vishwa Ranjan, former director general police, Chhattisgarh. Such an intensification will result in greater...

-The Hindu Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed...